Obesity is a common, serious, and costly disease. Following are some interesting statistics about obesity in the U.S.

93.3 million adults were affected by obesity in 2015-2016. 13.7 million

children and adolescents were affected by obesity in 2015-2016.

$147 billion

was the estimated annual medical cost of obesity in 2008.


is the additional medical cost obese individuals incur compared to those of normal weight.

112,000 deaths annually are attributable to obesity. 40 percent

of adults do not participate in any leisure-time physical activity.

100 pounds more than an individual’s ideal

body weight or having a body mass index (BMI) of </= 40

characterizes severe obesity. 25 percent

of individuals affected by severe obesity were being treated for six or more obesity-related conditions in 2002.

t 4PVSDFT data/childhood.html, https://www.obesityac- obesity-statistics-fact-sheets/


BD complete molecular portfolio for gastrointestinal infection (GI) with new viral panel. BD (Becton, Dickinson and Com- pany) announced the U.S. Food and Drug Administration (FDA) 510(k) clearance of its BD MAX enteric viral panel, a molecular diagnostic test for the direct qualitative detection and dif- ferentiation of enteric viral pathogens that cause viral gas- troenteritis. The company now offers a broad suite of solutions for the detection of intestinal conditions of bacterial, viral, and parasitic origin, in clinically relevant, targeted panels. Acute viral gastroenteritis can be contracted by virtually any patient and spread within close community settings such as daycare centers, nursing facili- ties, and cruise ships. Norovirus is the most common viral cause and accounts for 19 to 21 mil- lion cases of diarrheal illness annually in the United States, and 50 percent of all foodborne diarrheal outbreaks. Other viral causes include rotavirus, adenovirus, astrovirus, and sapovirus to varying degrees of prevalence. Diagnosing the underlying cause of diarrhea can play a critical role in patient management to isolate patients at risk of spreading infectious diarrhea to others and rule out other causes of infection in children, the elderly, or immunocompromised patients. The BD MAX enteric suite of molecular tests for the detec- tion of gastrointestinal bacteria, parasitic, or viral pathogens enable clinicians to perform targeted testing for patients based upon their symptoms and health history or expo- sure. This testing approach is supported by the Infectious Diseases Society of America (IDSA) guidelines. The BD MAX enteric viral panel is designed for targeted detection of the viral cause of infectious diar- rhea symptoms in all care set- tings and can detect norovirus, rotavirus, adenovirus, human astrovirus, and sapovirus. The enteric panels run on the BD MAX molecular system

and can return results in less than 3.5 hours, dramatically shortening time to results over traditional test methods. This shortened time to results allows clinicians to more quickly understand the cause of the patient’s illness.

1IBSNBDPHFOPNJD UFTUJOH Translational Software partners with Allscripts to provide pharmacogenomic testing for associates. Translational Software recently announced its partnership with Allscripts Healthcare Solutions, a practice management and electronic health record (EHR) technology company. The collaboration will provide free pharmacoge- nomic testing to all U.S.-based Allscripts associates.

When associates undergo a lengthy process of trial-and- error prescribing, employ- ers suffer the cost as well. Pharmacogenomic testing can help provide personalized guidance to individuals on medication efficacy and dos- age, which results in improv- ing medication adherence, increasing worker productivity, and reducing work absentee- ism. With studies demonstrat- ing the cost-effectiveness of pharmacogenomic-informed treatment, Allscripts recognized the value of associate wellness, satisfaction, and engagement in their overall health. Translational Software has

partnered with the telehealth company PWN Health and Allscripts subsidiary 2bPrecise to automate a new end-to-end pharmacogenomic healthcare benefit program. The new pro- gram is run on a portal built by Translational Software, where associates can place an order. PWN approves the order and sends out a testing kit. Once the kit is sent back by the associate, it is then routed to a testing laboratory in the Translational Software network selected by Allscripts. The labo- ratory performs the test and sends the interpreted results back to the portal, where they are accessible by the associate. If an associate is interested in

Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48